Literature DB >> 21900253

Polymeric structure and host Toll-like receptor 4 dictate immunogenicity of NY-ESO-1 antigen in vivo.

Yanan Liu1, Xiaoli Tian, Wolfgang W Leitner, Michael E Aldridge, Junying Zheng, Zhiya Yu, Nicholas P Restifo, Richard Weiss, Sandra Scheiblhofer, Chong Xie, Ren Sun, Genhong Cheng, Gang Zeng.   

Abstract

In search of intrinsic factors that contribute to the distinctively strong immunogenicity of a non-mutated cancer/testis antigen, we found that NY-ESO-1 forms polymeric structures through disulfide bonds. NY-ESO-1 binding to immature dendritic cells was dependent on its polymeric structure and involved Toll-like receptor-4 (TLR4) on the surface of immature dendritic cells in mouse and human. Gene gun-delivered plasmid encoding the wild-type NY-ESO-1 readily induced T cell-dependent antibody (Ab) responses in wild-type C57BL/10 mice but not TLR4-knock-out C57BL/10ScNJ mice. Disrupting polymeric structures of NY-ESO-1 by cysteine-to-serine (Cys-to-Ser) substitutions lead to diminished immunogenicity and altered TLR4-dependence in the induced Ab response. To demonstrate its adjuvant effect, NY-ESO-1 was fused with a major mugwort pollen allergen Art v 1 and a tumor-associated antigen, carbonic anhydrase 9. Plasmid DNA vaccines encoding the fusion genes generated robust immune responses against otherwise non-immunogenic targets in mice. Polymeric structure and TLR4 may play important roles in rendering NY-ESO-1 immunogenic and thus serve as a potent molecular adjuvant. NY-ESO-1 thus represents the first example of a cancer/testis antigen that is a also damage-associated molecular pattern.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21900253      PMCID: PMC3199455          DOI: 10.1074/jbc.M111.280123

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  22 in total

Review 1.  DNA vaccines for allergy treatment.

Authors:  Arnulf Hartl; Richard Weiss; Romana Hochreiter; Sandra Scheiblhofer; Josef Thalhamer
Journal:  Methods       Date:  2004-03       Impact factor: 3.608

2.  Surface calreticulin mediates muramyl dipeptide-induced apoptosis in RK13 cells.

Authors:  Dequan Chen; Donald E Texada; Chris Duggan; Chanping Liang; Thomas B Reden; Lakshmana M Kooragayala; Marlyn P Langford
Journal:  J Biol Chem       Date:  2005-04-06       Impact factor: 5.157

Review 3.  Tolerance, danger, and the extended family.

Authors:  P Matzinger
Journal:  Annu Rev Immunol       Date:  1994       Impact factor: 28.527

Review 4.  High-mobility group box 1 protein (HMGB1): nuclear weapon in the immune arsenal.

Authors:  Michael T Lotze; Kevin J Tracey
Journal:  Nat Rev Immunol       Date:  2005-04       Impact factor: 53.106

5.  Context-dependent hormone-refractory progression revealed through characterization of a novel murine prostate cancer cell line.

Authors:  Philip A Watson; Katharine Ellwood-Yen; Jennifer C King; John Wongvipat; Michelle M Lebeau; Charles L Sawyers
Journal:  Cancer Res       Date:  2005-12-15       Impact factor: 12.701

6.  Optimization of codon usage is required for effective genetic immunization against Art v 1, the major allergen of mugwort pollen.

Authors:  R Bauer; M Himly; A Dedic; F Ferreira; J Thalhamer; A Hartl
Journal:  Allergy       Date:  2003-10       Impact factor: 13.146

7.  Novel kidney cancer immunotherapy based on the granulocyte-macrophage colony-stimulating factor and carbonic anhydrase IX fusion gene.

Authors:  José M Hernández; Matthew H T Bui; Ken-Ryu Han; Hideki Mukouyama; Danielo G Freitas; David Nguyen; Randy Caliliw; Peter I Shintaku; Sun H Paik; Cho-Lea Tso; Robert A Figlin; Arie S Belldegrun
Journal:  Clin Cancer Res       Date:  2003-05       Impact factor: 12.531

8.  LAGE-1, a new gene with tumor specificity.

Authors:  B Lethé; S Lucas; L Michaux; C De Smet; D Godelaine; A Serrano; E De Plaen; T Boon
Journal:  Int J Cancer       Date:  1998-06-10       Impact factor: 7.396

9.  Tumor antigen expression in melanoma varies according to antigen and stage.

Authors:  Catherine Barrow; Judy Browning; Duncan MacGregor; Ian D Davis; Sue Sturrock; Achim A Jungbluth; Jonathan Cebon
Journal:  Clin Cancer Res       Date:  2006-02-01       Impact factor: 12.531

10.  Dominant B cell epitope from NY-ESO-1 recognized by sera from a wide spectrum of cancer patients: implications as a potential biomarker.

Authors:  Gang Zeng; Michael E Aldridge; Yu Wang; Allan J Pantuck; Allen Y Wang; Yue-xiang Liu; Yan Han; Yan-hua Yuan; Paul F Robbins; Steven M Dubinett; Jean B deKernion; Arie S Belldegrun
Journal:  Int J Cancer       Date:  2005-03-20       Impact factor: 7.396

View more
  4 in total

Review 1.  Cancer and innate immune system interactions: translational potentials for cancer immunotherapy.

Authors:  Yanan Liu; Gang Zeng
Journal:  J Immunother       Date:  2012-05       Impact factor: 4.456

2.  Gamma-interferon-inducible lysosomal thiol reductase is upregulated in human melanoma.

Authors:  Jennifer Nguyen; Richard Bernert; Kevin In; Paul Kang; Noemi Sebastiao; Chengcheng Hu; K Taraszka Hastings
Journal:  Melanoma Res       Date:  2016-04       Impact factor: 3.599

Review 3.  The effects of TLR activation on T-cell development and differentiation.

Authors:  Bo Jin; Tao Sun; Xiao-Hong Yu; Ying-Xiang Yang; Anthony E T Yeo
Journal:  Clin Dev Immunol       Date:  2012-06-07

Review 4.  Adjuvants in the Driver's Seat: How Magnitude, Type, Fine Specificity and Longevity of Immune Responses Are Driven by Distinct Classes of Immune Potentiators.

Authors:  Elke S Bergmann-Leitner; Wolfgang W Leitner
Journal:  Vaccines (Basel)       Date:  2014-04-10
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.